A month after landing Canadian approval for its updated neuromodulation implant to treat incontinence, Axonics is bringing the fourth-generation R20 device across the border. The FDA has approved the ...
Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...
Axonics today announced its R20 rechargeable sacral neuromodulation (SNM) system has received CE Mark approval for use in adults with overactive bladder and/or fecal incontinence. The implant can last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback